STUDY COMPARING THE COMBINED USE OF AVONEX AND COPAXONE

这个子项目是众多研究子项目之一

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether it is safe,tolerable and effective to use both interferone beta 1a (Avonex) and glatiramer acetate (Copaxone) for the treatment of relapsing multiple sclerosis (RRMS), rather than using only one agent alone. The standard dose for Avonex is 30 mcg administered once a week into the muscle. The standard dose of Copaxone is 20 mg administered daily under the skin. Both, treatments, Avonex and Copaxone are Food and Drug approved drugs. However, the combined use at their standard doses is not FDA approved.